- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07549438
Het voorspellen van het risico op partiële ciliaire blokkade na cataract- en goniosynechiolyse-chirurgie bij primaire geslotenhoekziekte (PCB-Risk)
Risicovoorspelling van gedeeltelijk ciliair blok na phacoemulsificatie gecombineerd met goniosynechiolyse bij primaire kamerhoekafsluitingsziekte: een prospectieve multicenterstudie
Primary angle-closure disease (PACD) is a major cause of vision loss, often treated with a combined surgery that removes the eye's natural lens (cataract surgery) and physically opens the eye's drainage system (goniosynechialysis). While effective, this surgery carries a small risk of a severe complication called ciliary block (or aqueous misdirection), where fluid builds up in the wrong part of the eye, pushing structures forward and causing high eye pressure. Recently, doctors have also noticed a "partial" form of this block, which can slowly cause the eye's drainage angle to close again without immediate severe symptoms.
The purpose of this prospective, observational study is to identify which patients are at the highest risk for developing classic or partial ciliary block after this combined surgery. Researchers will use standard, non-invasive eye imaging tools-such as ultrasound biomicroscopy (UBM) and optical coherence tomography (OCT)-to take highly detailed measurements of the front of the eye before surgery. They will specifically look at factors like the width of the anterior chamber, the thickness of the lens, and the eye's overall length. To ensure accuracy, patients with a very short eye length (less than 19mm) will not be included in the study.
Because this is an observational study, participation will not change a patient's standard surgical plan. Patients will undergo their scheduled surgery and be monitored for 12 months during routine follow-up visits to track their eye pressure, vision, and any structural changes in the eye.
By confirming which pre-surgery measurements predict ciliary block, researchers hope to validate a risk-warning model. This will help eye surgeons take preventive steps-such as administering specific medications like mannitol before surgery-to make the procedure safer and improve long-term outcomes for patients with PACD.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100044
- Zhiqiao Liang
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Patients with Primary Angle-Closure Disease (PACD)-spanning PACS, PAC, and PACG-who require surgical intervention with phacoemulsification combined with goniosynechialysis. Participants will be enrolled from the routine clinical care settings across multiple participating tertiary ophthalmic centers.
Beschrijving
Inclusion Criteria:
- Diagnosis of Primary Angle-Closure Disease (PACD), including Primary Angle-Closure Suspect (PACS), Primary Angle-Closure (PAC), or Primary Angle-Closure Glaucoma (PACG).
- Clinical indication for phacoemulsification combined with intraocular lens implantation and goniosynechialysis (Phaco+GSL), due to poorly controlled intraocular pressure, extensive peripheral anterior synechiae (PAS), or the presence of a clinically significant cataract.
- Ability to cooperate with required preoperative imaging examinations, including Ultrasound Biomicroscopy (UBM), IOLMaster, and Anterior Segment Optical Coherence Tomography (AS-OCT).
Exclusion Criteria:
- Secondary angle closure (e.g., neovascular glaucoma, uveitic glaucoma, iridocorneal endothelial [ICE] syndrome, or intraocular tumors/cysts).
- Specific lens abnormalities that confound anatomical assessment, including lens subluxation, hypermature intumescent cataract, or traumatic cataract.
- Previous intraocular surgery, including glaucoma filtering surgeries (e.g., trabeculectomy, tube shunts) or vitreoretinal surgeries (Note: Previous laser peripheral iridotomy is permitted).
- Use of systemic or topical medications known to affect ciliary body morphology or pupillary function (e.g., topiramate, cholinergic agonists) during the time of imaging.
- Poor quality or uninterpretable preoperative UBM or OCT images due to corneal opacity, edema, or other media opacities.
- Axial length shorter than 19mm.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
CB Group
Patients who develop classic or partial ciliary block (CB) during the 12-month follow-up period after phacoemulsification combined with goniosynechialysis. |
|
Non-CB Group
Patients who do not develop any form of ciliary block during the 12-month follow-up period after the surgery. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of Ciliary Block (Classic and Partial)
Tijdsspanne: Up to 12 months postoperatively
|
The primary outcome is the occurrence rate of classic or partial ciliary block (CB) following phacoemulsification combined with goniosynechialysis. Classic CB is diagnosed by a shallow or flat anterior chamber with elevated intraocular pressure, excluding pupillary block or choroidal effusion. Partial (subclinical) CB is defined by meeting at least two of the following criteria: an unexpected shallow anterior chamber (e.g., less than the expected 3mm or significantly smaller than the contralateral eye), a significant myopic shift (≥ -1.50D) indicating IOL-iris diaphragm anterior shift, UBM/OCT evidence of ciliary body anterior rotation, or significant deepening of the anterior chamber after cycloplegic administration. Intraoperative aqueous misdirection is also recorded as a primary endpoint event. |
Up to 12 months postoperatively
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- PekingUPHOphthalmology004
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .